Peptide Libraray

CMAP-L-232

General Information

DRACP ID DRACP01131

Peptide Name CMAP-L-232

Sequence KKFFKKMSFFFFKKK

Sequence Length 15

UniProt ID Not available

PubChem CID Not available

Origin Not available

Type Synthetic peptide

Classification

Active ACP

Activity Information

Cell Line	Disease	Cancer Classified	Activity	Assay	Testing Time	Literature
MDA-MB-231	Breast adenocarcinoma	Carcinoma	At a concentration of 100μM, the 24 h cell viability is approximately 79%(Duncan-test,P<0.01)	MTT assay	24 h	Patent

Hemolytic Activity Human red blood cells: no hemolytic activity at 12.5 μM, 25 μM, 50 μM, 100 μM

Normal (non-cancerous) Cytotoxicity Less toxic than CDDP on human normal MCF10A and 293FT

Target Not available

Affinity Not available

Mechanism Not available

Nature Anticancer

Structure Information

PDB ID Not available

Predicted Structure DRACP01131

Helicity Not available

Linear/Cyclic Linear

Disulfide/Other Bond Not available

N-terminal Modification Free

C-terminal Modification Free

Other Modification None

Chiral L

Physicochemical Information

Formula C104H154N22O17S

Absent amino acids ACDEGHILNPQRTVWY

Common amino acids K

Mass 226643

Pl 11.58

Basic residues 7

Acidic residues 0

Hydrophobic residues 6

Net charge 7

Boman Index -2202

Hydrophobicity -62.67

Aliphatic Index 0

Half Life
Mammalian: 1.3 hour
Yeast: 3 min
E.coli: 2 min

Extinction Coefficient cystines 0

Absorbance 280nm 0

Polar residues 1

Amino acid distribution

Literature Information

Literature 1

Pubmed ID Not available

Title Not available

Doi Not available

Year Not available

Patent

Patent ID CN106831946A

Patent Title Anticancer peptide as well as preparation method and application thereof

Other Iinformation Granted Patent; Family: 2s / 2ex; Family Jurisdictions: CN; Legal Status: Active; Application No: 201611198223; Filed: Dec 22, 2016; Published: Nov 10, 2020; Earliest Priority: Dec 22, 2016; Granted: Nov 10, 2020

Other Published ID CN106831946B